Atorvastatin is associated with reduced cisplatin-induced hearing loss
Atorvastatin is associated with reduced cisplatin-induced hearing loss
复制标题
DOI：
10.1172/jci142616
复制
发表时间：
2021-01-04
影响因子：
15.9
通讯作者：
Cunningham, Lisa L.
中科院分区：
文献类型：
--
作者：
Fernandez, Katharine A.;Allen, Paul;Cunningham, Lisa L.
背景资料。顺铂被广泛用于治疗成人和儿童癌症。它是临床上使用的耳毒性最强的药物，导致大约50%的接受治疗的患者永久听力损失。目前迫切需要预防顺铂所致听力损失的治疗方法。在小鼠身上的研究表明，同时使用他汀类药物可以减少顺铂引起的听力损失。方法：我们检测了277名接受顺铂治疗的头颈癌患者的听力阈值。在顺铂治疗开始和结束后90天内收集治疗前和治疗后的听力图。结果：在同时服用阿托伐他汀的患者中，9.7%的患者发生了2级或更高程度的顺铂所致的听力损失，而使用非他汀类药物的患者中，这一比例为29.4%(P 0.0001)。混合效应模型分析显示，使用阿托伐他汀显著降低了顺铂所致听力损失(P<0.05)。结论：我们的数据显示，在接受头颈癌治疗的成年人中，使用阿托伐他汀可降低顺铂所致听力损失的发生率和严重程度。
BACKGROUND. Cisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in approximately 50% of treated patients. There is a major need for therapies that prevent cisplatin-induced hearing loss. Studies in mice suggest that concurrent use of statins reduces cisplatin-induced hearing loss.METHODS. We examined hearing thresholds from 277 adults treated with cisplatin for head and neck cancer. Pretreatment and posttreatment audiograms were collected within 90 days of initiation and completion of cisplatin therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).RESULTS. Among patients on concurrent atorvastatin, 9.7% experienced a CTCAE grade 2 or higher cisplatin-induced hearing loss compared with 29.4% in nonstatin users (P 0.0001). A mixed-effect model analysis showed that atorvastatin use was significantly associated with reduced cisplatin-induced hearing loss (P 0.05).CONCLUSIONS. Our data indicate that atorvastatin use is associated with reduced incidence and severity of cisplatin-induced hearing loss in adults being treated for head and neck cancer.